Artificial Intelligence | Machine Learning | Natural Language Processing Eleven Therapeutics | Next Generation of RNAi Therapeutics


Enterprise, RNAi Drug Development, RNAi Therapeutics, Drug Research & Development Tel Aviv , Israel

Eleven Therapeutics

Artificial Intelligence | Machine Learning | Natural Language Processing


Eleven Therapeutics | Next Generation of RNAi Therapeutics

Eleven Therapeutics

RNAi Drug Development, RNAi Therapeutics, Drug Research & Development


Tel Aviv , Israel

Utilizing massively parallel combinatorial searches and AI algorithms to unleash the full power of RNAi. RNAi is a Nobel-prize-winning discovery that enables the repression of disease-causing genes, using small interfering RNA molecules (siRNA). These molecules are by nature digital, discrete, and highly specific to an active site. Their chemical topology naturally lends itself to combinatorial searches and AI algorithms, which become particularly powerful and predictive when combined with cost-effective DNA synthesis and sequencing technologies. Our platform leverages massively-parallel processes to map the chemical space and reveal the structure-activity relationship (SAR) of RNAi molecules. Employing big data, we optimize every component of siRNA molecules, including their safety, efficiency, and duration of effect. With hundreds of millions of respiratory disease patients in need of a cure, the lungs are the next frontier for RNAi therapeutics. While there are many broad applications for our platform, we are currently focused on developing the next generation of RNAi therapeutics to silence the disease-causing genes that are responsible for respiratory illnesses. In this process, we take a principled human genetics approach to our target selection, enabling our fully-programmable RNAi molecules to precisely eliminate the root causes of such diseases. We appreciate the interest that our valued partners and funders have found in our technologies. the development of therapies typically relies on a slow process of trial and error. At Eleven Tx, we orchestrate these technologies into highly-efficient processes for mapping the vast combinatorial space of potential RNAi molecules and precisely program the next generation of RNAi therapeutics. Capitalizing on these capabilities, we create tailor-made therapeutics that precisely silence disease-causing genes, treating the root cause of illnesses in humans.

 

B2B

26 to 50

Seed

$26.3M

Scaling Up

2020

 
 

Research & Consulting Services

Optimize Every Component of siRNA
Cost-Effective DNA Synthesis
Reveal Structure- Activity Relationship

Increase Efficiency
Increase Productivity

 
 

Analytics
Service

Yes

Active

 
 

   Machine Learning
   Natural Language Processing


Drug Discovery

Drug Discovery


Text

Text

Structured

Structured

 

   Software


Python

Python

C/C++

C/C++

AWS Redshift

AWS Redshift

Tensorflow

Tensorflow

Kubernetes

Kubernetes

Azure SQL

Azure SQL

Django

Django


Machine Learning Algorithm

Machine Learning Algorithm

Deep Learning Algorithm

Deep Learning Algorithm

 
 

View All

View All AI/ML Jobs

Senior Data Scientist

Remote , Remote

Senior Scientist - RNA Biology

Remote , Remote

 

AI/ML Professionals

Want to work at Eleven Therapeutics?

We can introduce you to the right person at Eleven Therapeutics

Talk to our Talent Team

 

6

1

$22M

Company was founded 2020 and it took almost 2 years (Aug 2022) to raise first external round

 
 

Date

Round

$ Raised

Investors

08/02/2022

Seed

$22M

Bill & Melinda Gates Foundation, Kindred Capital, NFX Bio, Harel Technology Investments, Entree Capital, Innovate UK

Date : 08/02/2022

Round: Seed

$ Raised: $22M

Investors: Bill & Melinda Gates Foundation, Kindred Capital, NFX Bio, Harel Technology Investments, Entree Capital, Innovate UK

 

Investors

Interested in researching Eleven Therapeutics?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Eleven Therapeutics

Request a Demo - Deal Souring Platform

 
Yaniv Erlich

Yaniv Erlich
Chief Executive Officer

Shaul Ilan

Shaul Ilan
Co-Founder / COO & BD

Roei Pinhas

Roei Pinhas
Director of Finance

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Eleven Therapeutics